Suven Pharmaceuticals Limited (NSE: SUVENPHAR)

Suven Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	-	472.31	648.03	445.64	71.82	116.95
Trading Asset Securities	-	7,739	4,189	4,812	1,806	306.73
Cash & Short-Term Investments	8,211	8,211	4,837	5,258	1,878	423.69
Cash Growth	68.63%	69.75%	-8.00%	180.01%	343.20%	113.55%
Accounts Receivable	-	1,337	1,109	2,364	1,024	1,172
Other Receivables	-	562.28	665.92	480.04	516.22	358.79
Receivables	-	1,907	1,777	2,846	1,542	1,533
Inventory	-	2,326	3,306	3,000	2,127	1,863
Prepaid Expenses	-	49.21	86.28	64	43.97	38.59
Other Current Assets	-	138.34	103.79	111.67	56.72	58.28
Total Current Assets	-	12,632	10,110	11,279	5,648	3,916
Property, Plant & Equipment	-	7,868	7,662	5,620	5,349	4,555
Long-Term Investments	-	1,306	1,171	1,171	3,612	3,075
Goodwill	-	602.58	602.58	-	-	-
Other Intangible Assets	-	16.67	19.32	22.36	25.91	29.4
Other Long-Term Assets	-	116.09	91.64	203.02	109.54	151.99
Total Assets	-	22,541	19,657	18,296	14,745	11,728
Accounts Payable	-	423.57	700.92	1,059	829.31	710.56
Accrued Expenses	-	151.87	128.17	266	198.03	136.07
Short-Term Debt	-	385.75	445.98	-	641.89	520.38
Current Portion of Long-Term Debt	-	-	200	671.33	414.48	420
Current Portion of Leases	-	51.86	4.79	10.91	10.68	4.04
Current Income Taxes Payable	-	-	2.94	36.42	-	52.54
Current Unearned Revenue	-	6.89	8.08	-	-	-
Other Current Liabilities	-	49.02	96.79	59.27	103.08	160.17
Total Current Liabilities	-	1,069	1,588	2,103	2,197	2,004
Long-Term Debt	-	-	45.64	284.4	355.91	912.53
Long-Term Leases	-	212.36	7	4.63	7.39	5.12
Long-Term Deferred Tax Liabilities	-	647.91	582.35	543.15	309.33	275.97
Other Long-Term Liabilities	-	97.68	82.95	77.85	44.99	40.86
Total Liabilities	-	2,034	2,306	3,024	2,937	3,281
Common Stock	-	254.57	254.57	254.57	254.57	127.28
Additional Paid-In Capital	-	1,096	1,096	1,096	1,096	1,223
Retained Earnings	-	18,894	15,894	13,820	10,308	6,947
Comprensive Income & Other	-	262.39	107.17	101.65	150.09	150.11
Shareholders' Equity	20,507	20,507	17,352	15,272	11,808	8,448
Total Liabilities & Equity	-	22,541	19,657	18,296	14,745	11,728
Total Debt	649.96	649.96	703.41	971.27	1,430	1,862
Net Cash (Debt)	7,561	7,561	4,134	4,287	447.4	-1,438
Net Cash Growth	81.50%	82.91%	-3.56%	858.10%	-	-
Net Cash Per Share	29.71	29.70	16.24	16.84	1.76	-5.65
Filing Date Shares Outstanding	254.27	254.56	254.56	254.56	254.56	254.56
Total Common Shares Outstanding	254.27	254.56	254.56	254.56	254.56	254.56
Working Capital	-	11,563	8,523	9,176	3,450	1,913
Book Value Per Share	80.56	80.56	68.16	59.99	46.39	33.18
Tangible Book Value	19,887	19,887	16,730	15,249	11,782	8,418
Tangible Book Value Per Share	78.12	78.12	65.72	59.90	46.28	33.07
Land	-	150.46	150.46	150.46	150.46	150.46
Buildings	-	2,209	2,200	1,813	1,411	1,226
Machinery	-	5,607	5,410	4,750	3,909	2,990
Construction In Progress	-	1,790	1,651	299.94	961.49	1,016
Leasehold Improvements	-	42.6	-	-	-	-

Source: S&P Capital IQ. Standard template. Financial Sources.